Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody

Casdozokitug has demonstrated anti-tumor activity alone and in combination with an anti-PD-1 antibody; two of nine squamous NSCLC patients had confirmed partial responses Data support continued evaluation of casdozokitug in combination with...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials